UTHR Q1 2020 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$356M-1.7% YoY

Gross Profit

$333M93.4% margin

Operating Income

$167M46.8% margin

Net Income

$138M38.6% margin

EPS (Diluted)

$3.12

QoQ Revenue Growth

+14.5%

Cash Flow

Operating Cash Flow

$215M

Free Cash Flow

$202M

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$4.0B

Total Liabilities

$1.1B

Stockholders' Equity

$2.9B

Cash & Equivalents

$875M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$356M	$363M	-1.7%
Gross Profit	$333M	$334M	-0.2%
Operating Income	$167M	-$656M	+125.4%
Net Income	$138M	-$495M	+127.8%

Revenue Segments

Remodulin

$145M41%

Tyvaso

$103M29%

Orenitram

$69M19%

Unituxin

$27M7%

Adcirca

$13M4%

Geographic Segments

U

$327M92%

European Union And Others

$30M8%